PharmacoEconomics

1997 - 2025

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 29, issue 12, 2011

Erratum to: The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK pp. 1014-1014

Á Benedict, L Verdian and G Maclaine

QALYs and Carers pp. 1015-1023

Hareth Al-Janabi, Terry Flynn and Joanna Coast

Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease pp. 1025-1049

Judith Dams, Bernhard Bornschein, Jens Reese, Annette Conrads-Frank, Wolfgang Oertel, Uwe Siebert and Richard Dodel

Cost-Effectiveness Analysis of Prophylactic Lamivudine Use in Preventing Vertical Transmission of Hepatitis B Virus Infection pp. 1063-1073

Hui-Fang Hung and Hsiu-Hsi Chen

Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective pp. 1075-1091

Helen Dakin, Morris Sherman, Scott Fung, Carrie Fidler and Anthony Bentley

Volume 29, issue 11, 2011

Sample Size Determination for Cost-Effectiveness Trials pp. 933-949

Andrew Willan

Willingness to Pay for Adverse Drug Event Regulatory Actions pp. 963-975

Jacoline Bouvy, Just Weemers, Huub Schellekens and Marc Koopmanschap

Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma pp. 977-988

Ateesha Mohamed, A. Hauber and Maureen Neary

Rotavirus Vaccine RIX4414 (Rotarix™) pp. 989-1009

Greg Plosker

Volume 29, issue 10, 2011

A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease pp. 839-861

Joseph Menzin, Lisa Lines, Daniel Weiner, Peter Neumann, Christine Nichols, Lauren Rodriguez, Irene Agodoa and Tracy Mayne

Does the Market Share of Generic Medicines Influence the Price Level? pp. 875-882

Pieter Dylst and Steven Simoens

Volume 29, issue 9, 2011

Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand pp. 781-806

Naiyana Praditsitthikorn, Yot Teerawattananon, Sripen Tantivess, Supon Limwattananon, Arthorn Riewpaiboon, Saibua Chichareon, Nantakan Ieumwananonthachai and Viroj Tangcharoensathien

Volume 29, issue 8, 2011

Cost-of-Illness Studies pp. 653-671

Allison Larg and John Moss

Cost Estimation of Cardiovascular Disease Events in the US pp. 693-704

Amy O’Sullivan, Jaime Rubin, Joshua Nyambose, Andreas Kuznik, David Cohen and David Thompson

Volume 29, issue 7, 2011

Prioritizing Comparative Effectiveness Research pp. 555-561

Afschin Gandjour

Presenting Evidence and Summary Measures to Best Inform Societal Decisions When Comparing Multiple Strategies pp. 563-577

Simon Eckermann and Andrew Willan

Unit Costs for Delivery of Antiretroviral Treatment and Prevention of Mother-to-Child Transmission of HIV pp. 579-599

Omar Galarraga, Veronika Wirtz, Alejandro Figueroa-Lara, Yared Santa-Ana-Tellez, Ibrahima Coulibaly, Kirsi Viisainen, Antonieta Medina-Lara and Eline Korenromp

Do Productivity Costs Matter? pp. 601-619

Marieke Krol, Jocé Papenburg, Marc Koopmanschap and Werner Brouwer

Medication Costs to Private Insurers of Diversion of Medications for Attention-Deficit Hyperactivity Disorder pp. 621-635

Arnie Aldridge, Larry Kroutil, Alexander Cowell, Daniel Reeves and David Brunt

Volume 29, issue 5, 2011

Erratum to: Cost Effectiveness of Budesonide/Formoterol Added to Tiotropium Bromide versus Placebo Added to Tiotropium Bromide in Patients with Chronic Obstructive Pulmonary Disease pp. 414-414

Nicole Mittmann, Paul Hernandez, Carl Mellström, Lance Brannman and Tobias Welte

Volume 29, issue 4, 2011

Sample Size and Power for Cost-Effectiveness Analysis (Part 2) pp. 287-296

Henry Glick

Volume 29, issue 3, 2011

Sample Size and Power for Cost-Effectiveness Analysis (Part 1) pp. 189-198

Henry Glick

Cost Effectiveness of Pneumococcal Conjugate Vaccination against Acute Otitis Media in Children pp. 199-211

Chantal Boonacker, Pieter Broos, Elisabeth Sanders, Anne Schilder and Maroeska Rovers

Comparing Methods of Data Synthesis pp. 239-250

Mark Oppe, Maiwenn Al and Maureen Rutten-Mölken

Volume 29, issue 2, 2011

Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration pp. 107-131

Paul Mitchell, Lieven Annemans, Richard White, Meghan Gallagher and Simu Thomas

Volume 29, issue 1, 2011

Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis pp. 1-15

Martin Hoyle

Effects of Reference Pricing in Pharmaceutical Markets pp. 17-33

Matteo Galizzi, Simone Ghislandi and Marisa Miraldo

Calibrating Models in Economic Evaluation pp. 35-49

Tazio Vanni, Jonathan Karnon, Jason Madan, Richard White, W. Edmunds, Anna Foss and Rosa Legood

Calibrating Models in Economic Evaluation pp. 51-62

Jonathan Karnon and Tazio Vanni

Availability of and Access to Orphan Drugs pp. 63-82

Carl Blankart, Tom Stargardt and Jonas Schreyögg

Is There a Role for Pharmacoeconomics in Developing Countries? pp. 83-84

Asrul Shafie and Mohamed Hassali

The Authors’ Reply pp. 84-86

Zaheer-Ud-Din Babar and Shane Scahill

Volume 28, issue 12, 2010

A Review and Critique of Studies Reporting Utility Values for Schizophrenia-Related Health States pp. 1109-1121

Ifigeneia Mavranezouli

Volume 28, issue 11, 2010

An Analysis of NICE’s ‘Restricted’ (or ‘Optimized’) Decisions pp. 987-993

Phill O’Neill and Nancy Devlin

Methods of Model Calibration pp. 995-1000

Douglas Taylor, Vivek Pawar, Denise Kruzikas, Kristen Gilmore, Ankur Pandya, Rowan Iskandar and Milton Weinstein

Cost Effectiveness of Pharmacogenomics pp. 1001-1013

William Wong, Josh Carlson, Rahber Thariani and David Veenstra

Economic Efficiency of Genetic Screening to Inform the Use of Abacavir Sulfate in the Treatment of HIV pp. 1025-1039

Teresa Kauf, Raymond Farkouh, Stephanie Earnshaw, Maria Watson, Penny Maroudas and Mike Chambers

Economic Evaluation of Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Italy pp. 1041-1054

Mario Eandi, Lorenzo Pradelli, Sergio Iannazzo, Silvia Chiroli and Giuseppe Pontoriero

Cost Effectiveness of Imiquimod 5% Cream Compared with Methyl Aminolevulinate-Based Photodynamic Therapy in the Treatment of Non-Hyperkeratotic, Non-Hypertrophic Actinic (Solar) Keratoses A Decision Tree Model pp. 1055-1064

Edward Wilson

Volume 28, issue 10, 2010

International Comparison of Comparative Effectiveness Research in Five Jurisdictions pp. 813-830

Adrian Levy, Craig Mitton, Karissa Johnston, Brian Harrigan and Andrew Briggs

Comparative Effectiveness Regulations and Pharmaceutical Innovation pp. 877-887

John Vernon, Joseph Golec and J. Stevens

Comparative Effectiveness Research pp. 915-922

Marc Berger and David Grainger

Comparative Effectiveness Without Head-to-Head Trials pp. 935-945

James Signorovitch, Eric Wu, Andrew Yu, Charles Gerrits, Evan Kantor, Yanjun Bao, Shiraz Gupta and Parvez Mulani

No Head-to-Head Trial? Simulate the Missing Arms pp. 957-967

J.Jaime Caro and K. Ishak

Volume 28, issue 9, 2010

Using Conjoint Analysis and Choice Experiments to Estimate QALY Values pp. 711-722

Terry Flynn

Cost Effectiveness of Adjunctive Quetiapine Fumarate Extended-Release Tablets with Mood Stabilizers in the Maintenance Treatment of Bipolar I Disorder pp. 751-764

Tatia Woodward, Eskinder Tafesse, Peter Quon and Arthur Lazarus

An Economic Evaluation of Colesevelam when Added to Metformin-, Insulinor Sulfonylurea-Based Therapies in Patients with Uncontrolled Type 2 Diabetes Mellitus pp. 765-780

W. Simons and Michael Hagan

Volume 28, issue 8, 2010

Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms pp. 615-628

Joseph Golec and John Vernon

Economic Burden of Epilepsy among the Privately Insured in the US pp. 675-685

Jasmina Ivanova, Howard Birnbaum, Yohanne Kidolezi, Ying Qiu, David Mallett and Sue Caleo

Volume 28, issue 7, 2010

Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement pp. 521-538

Alok Kapoor, Warren Chuang, Nila Radhakrishnan, Kenneth Smith, Dan Berlowitz, Jodi Segal, Jeffrey Katz and Elena Losina

The State of Health Economic Evaluation Research in Nigeria pp. 539-553

Paul Gavaza, Karen Rascati, Abiola Oladapo and Star Khoza

Cost Effectiveness of Leukotriene Receptor Antagonists versus Inhaled Corticosteroids for Initial Asthma Controller Therapy pp. 585-595

Edward Wilson, Erika Sims, Stanley Musgrave, Lee Shepstone, Annie Blyth, Jamie Murdoch, H. Mugford, Elizabeth Juniper, Jon Ayres, Stephanie Wolfe, Daryl Freeman, Richard Gilbert, Ian Harvey, Elizabeth Hillyer and David Price

Cost Effectiveness of Leukotriene Receptor Antagonists versus Long-Acting Beta-2 Agonists as Add-On Therapy to Inhaled Corticosteroids for Asthma pp. 597-608

Edward Wilson, David Price, Stanley Musgrave, Erika Sims, Lee Shepstone, Jamie Murdoch, H. Mugford, Annie Blyth, Elizabeth Juniper, Jon Ayres, Stephanie Wolfe, Daryl Freeman, Richard Gilbert, Elizabeth Hillyer and Ian Harvey

Volume 28, issue 6, 2010

Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia? pp. 463-475

Lesley Chim, Patrick Kelly, Glenn Salkeld and Martin Stockler

Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis pp. 477-487

Roisin Adams, Cathal Walsh, Douglas Veale, Barry Bresnihan, Oliver FitzGerald and Michael Barry

Cost Effectiveness of 5-Alpha Reductase Inhibitors for the Prevention of Prostate Cancer in Multiple Patient Populations pp. 489-505

Stephanie Earnshaw, Cheryl McDade, Libby Black, Christopher Bell and Michael Kattan

Does the Inclusion of a Cost Attribute Result in Different Preferences for the Surgical Treatment of Primary Basal Cell Carcinoma? pp. 507-520

Brigitte Essers, Debby Helvoort-Postulart, Martin Prins, Martino Neumann and Carmen Dirksen

Volume 28, issue 5, 2010

Health Economic Burden of Patients with Restless Legs Syndrome in a German Ambulatory Setting pp. 381-393

Richard Dodel, Svenja Happe, Ines Peglau, Geert Mayer, Juergen Wasem, Jens-Peter Reese, Guido Giani, Max Geraedts, Claudia Trenkwalder, Wolfgang Oertel and Karin Stiasny-Kolster

Direct and Indirect Costs of Non-Vertebral Fracture Patients with Osteoporosis in the US pp. 395-409

Crystal Pike, Howard Birnbaum, Matt Schiller, Hari Sharma, Russel Burge and Eric Edgell

Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer’s Disease pp. 411-427

Denis Getsios, Steve Blume, K. Ishak and Grant Maclaine

Economic Content in Medical Journal Advertisements for Medical Devices and Prescription Drugs pp. 429-438

D. Ackerly, Seth Glickman and Kevin Schulman

Volume 28, issue 3, 2010

The Cost Effectiveness of Rufinamide in the Treatment of Lennox-Gastaut Syndrome in the UK pp. 185-199

Ágnes Benedict, Lara Verdian and Grant Maclaine

Volume 28, issue 1, 2010

Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma pp. 35-46

Eric Deconinck, Houda Miadi-Fargier, Claude Pen and Pauline Brice

Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US pp. 47-60

Virginia Rosen, Douglas Taylor, Hemangi Parekh, Ankur Pandya, David Thompson, Andreas Kuznik, David Waters, Michael Drummond and Milton Weinstein

A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing pp. 61-74

Lisa Meckley, James Gudgeon, Jeffrey Anderson, Marc Williams and David Veenstra